NORTHWEST BIOTHERAPEUTICS INC
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336.0K | $623.0K | $1.7M | $1.5M | $809.0K | $772.0K | $10.0K | $10.0K |
| Cost of Revenue | — | — | — | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | $809.0K | $772.0K | $10.0K | $10.0K |
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Expenses | ||||||||
| Research & Development | $33.5M | $60.1M | $103.1M | $85.6M | $43.9M | $28.9M | $13.5M | $9.9M |
| SG&A Expense | $12.5M | $10.9M | $18.3M | $17.0M | $12.4M | $15.7M | $13.3M | $5.5M |
| Operating Income | $-54.7M | $-79.3M | $-126.3M | $-101.1M | $-55.5M | $-43.8M | $-26.8M | $-15.4M |
| Operating Margin | -16,273.2% | -12,723.3% | -7,261.9% | -6,956.2% | -6,857.1% | -5,676.8% | -267,870.0% | -153,540.0% |
| Interest Expense | $5.5M | $3.8M | $4.2M | $996.0K | $842.0K | $13.4M | $7.6M | $7.9M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net Income | $-73.1M | $-80.2M | $-114.7M | $-135.6M | $-65.8M | $-67.3M | $-32.8M | $-27.4M |
| Net Margin | -21,768.8% | -12,875.4% | -6,598.1% | -9,328.3% | -8,132.1% | -8,720.2% | -328,300.0% | -273,680.0% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.01 | — |
| Shares Outstanding (Basic) | 365.08B | 174.27B | 106.40B | 76.54B | 50.69B | 27.39B | 104.56B | 74.44B |
| Shares Outstanding (Diluted) | 365.08B | 174.27B | 106.40B | 76.54B | 50.69B | 27.39B | 104.56B | 74.44B |
| Dividends Per Share | — | — | — | — | — | — | — | — |